What did @brianas1998 actually say?
Honestly, not much, at least not medically. The transcript itself is mostly celebratory filler: "that ass perfect, baby" and "I'm all ugly" alongside a caption declaring she's "locked in for life" with compounded tirzepatide. The factual content lives in the caption and hashtags, not the spoken words. So what we're fact-checking is the implied claim: that compounded tirzepatide is a long-term, reliable weight loss solution worth committing to indefinitely. That's worth examining seriously, because 2.3 million people saw it.
The enthusiasm is understandable. Tirzepatide produces real, significant weight loss results. But "locked in for life" with a compounded version of a drug carries regulatory, clinical, and safety implications that a transformation video won't cover. Let's get into it.
Does the science back up long-term tirzepatide use?
The data on tirzepatide for weight loss is genuinely strong, but it comes with a significant catch: stopping the drug largely reverses the results. That changes what "for life" actually means.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15mg produced average weight loss of 20.9% of body weight over 72 weeks. That's meaningful. However, the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) followed participants who stopped tirzepatide after initial weight loss and found they regained about two-thirds of lost weight within a year. So if you're truly committing "for life," you may be acknowledging, consciously or not, that this is a lifelong medication, not a course of treatment. That's not necessarily wrong, but it's a conversation that deserves more than a TikTok caption.
- Tirzepatide is a dual GIP and GLP-1 receptor agonist, approved by the FDA as Zepbound for chronic weight management.
- Long-term cardiovascular and safety data beyond three years remains limited compared to older agents like semaglutide.
What did they get wrong, or right?
The creator didn't make explicit medical claims, which is worth crediting. She didn't say tirzepatide cures anything, didn't quote a dose, and didn't tell followers to get it. The video reads more like a personal celebration than medical advice, and that distinction matters.
What's missing, though, is the word "compounded." Compounded tirzepatide is not FDA-approved. It was permitted under shortage provisions, but the FDA declared the tirzepatide shortage resolved in late 2024, which triggered a phase-out of compounded versions. Compounded drugs are not required to demonstrate the same potency, sterility, or bioavailability as brand-name Zepbound. The FDA has issued specific warnings about compounded GLP-1 medications, citing reports of dosing errors and adverse events. Calling yourself "locked in for life" with a compounded product, without any of that context, is where this video quietly misleads a large audience. Not through lies, but through omission.
What should you actually know?
If you're considering tirzepatide for weight loss, the evidence supports its effectiveness, but the version matters enormously right now.
Compounded tirzepatide occupies a legally and clinically murky space in 2025. The FDA's resolution of the shortage means telehealth platforms and compounding pharmacies are under pressure to discontinue it, though some continue operating under 503A or 503B exemptions. Patients who switch from compounded to brand-name Zepbound may find significant cost differences, since Zepbound's list price exceeds $1,000 per month without insurance coverage.
- Ask your prescriber specifically whether the product comes from an FDA-registered 503B outsourcing facility, not just any compounding pharmacy.
- Understand that weight regain after stopping is not a personal failure. It reflects the drug's mechanism. Discontinuation should be planned, not abrupt.
- GLP-1 and GIP agonists affect gastric emptying, appetite signaling, and potentially cardiac function. These are not wellness supplements. They require medical supervision.
The SCALE and SURMOUNT trial programs are real. The weight loss is real. But a 2.3 million-view video celebrating a compounded version of a drug that regulators are actively pulling from the market is worth at least a few seconds of scrutiny before the next weigh-in post.